Get the Stockscreener App
91.82
2.06%
-1.93
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $91.82, with a volume of 1.35M.
It is down -2.06% in the last 24 hours and down -18.89% over the past month.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$93.75
Open:
$93.25
24h Volume:
1.35M
Relative Volume:
1.30
Market Cap:
$11.73B
Revenue:
$2.72B
Net Income/Loss:
$254.30M
P/E Ratio:
44.43
EPS:
2.0665
Net Cash Flow:
$564.37M
1W Performance:
-1.29%
1M Performance:
-18.89%
6M Performance:
-22.87%
1Y Performance:
-8.68%
1-Day Range:
$91.74
$93.86
1-Week Range:
$91.74
$97.98
52-Week Range:
$89.61
$129.50
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
91.82 | 11.73B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com
Revvity price target lowered to $120 from $140 at Bernstein - TipRanks
Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Green Market Report
Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq
What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus
BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus
KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener
Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus
Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener
KeyBanc maintains Overweight rating on Revvity stock at $145 target - Investing.com Australia
KeyBanc maintains Overweight rating on Revvity stock at $145 target By Investing.com - Investing.com South Africa
KeyBanc Adjusts Price Target on Revvity to $145 From $135, Keeps Overweight Rating - MarketScreener
Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price - simplywall.st
Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery - Technology Networks
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Technology Networks
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN
Revvity Q1 2025 Earnings Preview: CEO and CFO to Detail Financial Performance - Stock Titan
FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo - Yahoo
Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus
FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa
What's Going On With Revvity Stock Today? - Benzinga
(RVTY) Investment Analysis - news.stocktradersdaily.com
Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating - MarketScreener
FDA Approves Revvity’s Improved Automated Latent Tuberculosis Test - Medical Product Outsourcing
Revvity gets FDA nod for its automated tuberculosis test (RVTY:NYSE) - Seeking Alpha
Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test - MarketScreener
FDA greenlights Revvity’s TB diagnostic platform - Investing.com India
Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test - MarketScreener
Game-Changing TB Test: Revvity's New FDA-Approved System Cuts Testing Time by 70% - Stock Titan
Pictet Asset Management Holding SA Has $125.17 Million Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Is Revvity Stock Underperforming the Nasdaq? - MSN
High Content Screening/Imaging Technology Analysis and Global Market Forecasts 2025-2029 with Danaher, Revvity, Thermo Fischer Scientific, Agilent Technologies and Yokogawa LeadingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Revvity Stock Underperforming The Nasdaq? - Barchart.com
Is Revvity Gaining or Losing Market Support? - Benzinga
Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England - Technology Networks
Revvity Stock Tumbles Despite Expanding Genomics England Alliance - MSN
The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years - Yahoo Finance
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - BioSpace
Revvity Expands Alliance with Genomics England -March 20, 2025 at 02:10 pm EDT - MarketScreener
Massive Breakthrough: Revvity's 100K Newborn Genetic Screening Program Targets 200 Rare Diseases - StockTitan
May 16th Options Now Available For Revvity (RVTY) - Nasdaq
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Simply Wall St
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity's AI-Powered Cellular Imaging & Research Antibodies - openPR
KeyBanc Adjusts Price Target on Revvity to $145 From $135, Maintains Overweight Rating - MarketScreener
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):